MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Dr Reddy's Laboratories Ltd-ADR

Chiusa

SettoreSettore sanitario

13.24 0.61

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13.01

Massimo

13.24

Metriche Chiave

By Trading Economics

Entrata

1.5B

14B

Vendite

3.4B

84B

P/E

Media del settore

17.587

63.778

EPS

16.936

Rendimento da dividendi

0.72

Margine di Profitto

16.795

Dipendenti

27,048

EBITDA

2.4B

24B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+38.3% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.72%

2.39%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

8.8B

11B

Apertura precedente

12.63

Chiusura precedente

13.24

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Dr Reddy's Laboratories Ltd-ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 giu 2024, 13:33 UTC

Acquisizioni, Fusioni, Takeovers

Haleon to Sell Nicotine-Quitting Aid Business for $634 Million -- Update

26 giu 2024, 12:32 UTC

Acquisizioni, Fusioni, Takeovers

Haleon to Sell Nicotine-Quitting Aid Business for $634 Million

25 apr 2024, 10:32 UTC

Utili

Nestle India Reports Rise in Quarterly Profit, Announces JV With Dr. Reddy's Laboratories

23 gen 2025, 17:46 UTC

Utili

Dr. Reddy's 3Q Net Attributable to Equity Holders of Parent Company INR14.13B

23 gen 2025, 17:42 UTC

Utili

Dr. Reddy's 3Q Rev INR83.59B

5 nov 2024, 11:01 UTC

Utili

Dr. Reddy's Laboratories 1H Rev INR156.89B Vs. INR136.19B >RDY

5 nov 2024, 11:00 UTC

Utili

Dr. Reddy's Laboratories 1H Net INR26.47B Vs. Net INR28.825B >RDY

5 nov 2024, 10:57 UTC

Utili

Dr. Reddy's Laboratories 2Q Net INR12.55B Vs. Net INR14.80B >RDY

5 nov 2024, 10:57 UTC

Utili

Dr. Reddy's Laboratories 2Q Rev INR80.16B Vs. INR68.80B >RDY

26 giu 2024, 11:54 UTC

Acquisizioni, Fusioni, Takeovers

Haleon: All Other 2024 Guidance Unchanged

26 giu 2024, 11:54 UTC

Acquisizioni, Fusioni, Takeovers

Haleon: Sale Will Dilute 2024 Rev by 0.5%, Adj Oper Pft by 1%

26 giu 2024, 11:52 UTC

Acquisizioni, Fusioni, Takeovers

Haleon: Sale Allow For NRT Exit Outside US, Trims Business Complexity

26 giu 2024, 11:51 UTC

Acquisizioni, Fusioni, Takeovers

Haleon: Deal Expected to Complete Early 4Q

26 giu 2024, 11:50 UTC

Acquisizioni, Fusioni, Takeovers

Haleon: Use of Proceeds Will Be in Line With Capital Allocation Priorities

26 giu 2024, 11:49 UTC

Acquisizioni, Fusioni, Takeovers

Haleon: Deal Structure Upfront Cash GBP458M, GBP42M Performance-Based Payable

26 giu 2024, 11:48 UTC

Acquisizioni, Fusioni, Takeovers

Haleon: Portfolio Includes Nicotinell, Nicabate, Habitrol and Thrive Available in Gum, Lozenge

26 giu 2024, 11:47 UTC

Acquisizioni, Fusioni, Takeovers

Haleon: Deal Worth GBP500M With Additional Proceeds From Inventory Transfer

26 giu 2024, 11:46 UTC

Acquisizioni, Fusioni, Takeovers

Haleon to Sell Non-US Nicotine Replacement Therapy Business to Dr. Reddy's Laboratories

7 mag 2024, 10:56 UTC

Utili

Dr. Reddy's Laboratories 4Q Net INR13.07B Vs. Net INR9.59B >500124.BY

7 mag 2024, 10:55 UTC

Utili

Dr. Reddy's Laboratories 4Q Rev INR70.83B Vs. INR62.97B >500124.BY

Confronto tra pari

Modifica del prezzo

Dr Reddy's Laboratories Ltd-ADR Previsione

Obiettivo di Prezzo

By TipRanks

38.3% in crescita

Previsioni per 12 mesi

Media 18.2 USD  38.3%

Alto 19.4 USD

Basso 17 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Dr Reddy's Laboratories Ltd-ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

2

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

13.12 / 13.21Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Weak Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.